TW200744628A - Stimulators of factor X activated (FXA) as new topical antihemorrhagic agents - Google Patents

Stimulators of factor X activated (FXA) as new topical antihemorrhagic agents

Info

Publication number
TW200744628A
TW200744628A TW095128519A TW95128519A TW200744628A TW 200744628 A TW200744628 A TW 200744628A TW 095128519 A TW095128519 A TW 095128519A TW 95128519 A TW95128519 A TW 95128519A TW 200744628 A TW200744628 A TW 200744628A
Authority
TW
Taiwan
Prior art keywords
fxa
activated
factor
stimulators
new topical
Prior art date
Application number
TW095128519A
Other languages
English (en)
Other versions
TWI441645B (zh
Inventor
Javier Pedreno Egea
Luis Caveda Catasus
Original Assignee
Thrombotargets Europe Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombotargets Europe Sl filed Critical Thrombotargets Europe Sl
Publication of TW200744628A publication Critical patent/TW200744628A/zh
Application granted granted Critical
Publication of TWI441645B publication Critical patent/TWI441645B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095128519A 2005-08-03 2006-08-03 作為新穎之局部用止血劑的活化型因子Ｘ（ＦＸａ）刺激劑 TWI441645B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05380179A EP1749536A1 (en) 2005-08-03 2005-08-03 Activated factor X stimulants as new antihemorrhagic agents for topical use

Publications (2)

Publication Number Publication Date
TW200744628A true TW200744628A (en) 2007-12-16
TWI441645B TWI441645B (zh) 2014-06-21

Family

ID=35916272

Family Applications (2)

Application Number Title Priority Date Filing Date
TW095128520A TW200744633A (en) 2005-08-03 2006-08-03 Direct and indirect effector cell protease receptor-1 (EPR-1) inhibitors as antiplatelet agents
TW095128519A TWI441645B (zh) 2005-08-03 2006-08-03 作為新穎之局部用止血劑的活化型因子Ｘ（ＦＸａ）刺激劑

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW095128520A TW200744633A (en) 2005-08-03 2006-08-03 Direct and indirect effector cell protease receptor-1 (EPR-1) inhibitors as antiplatelet agents

Country Status (13)

Country Link
EP (3) EP1749536A1 (zh)
JP (2) JP5268638B2 (zh)
KR (1) KR101362993B1 (zh)
CN (1) CN101291686B (zh)
AU (1) AU2006274979B2 (zh)
BR (1) BRPI0616535B8 (zh)
CA (1) CA2617534C (zh)
DK (1) DK1917026T3 (zh)
ES (1) ES2468225T3 (zh)
HK (1) HK1119569A1 (zh)
PL (1) PL1917026T3 (zh)
TW (2) TW200744633A (zh)
WO (2) WO2007014771A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772371B2 (en) * 2005-08-03 2010-08-10 Thrombotargets Corporation Stimulators of Factor X activated (FXa) as new topical antihemorrhagic agents
EP2745852A1 (en) * 2012-12-21 2014-06-25 Thrombotargets Europe, S.L. Sealant compositions
EP2759305A1 (en) * 2013-01-24 2014-07-30 Thrombotargets Europe, S.L. Hemostatic compositions
CN110133303B (zh) * 2019-05-13 2023-04-07 深圳优迪生物技术有限公司 凝血酶原时间测定试剂及其应用
CN112433057B (zh) * 2020-11-10 2023-06-09 北京美创新跃医疗器械有限公司 一种狼疮抗凝物的筛选试剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721618A (en) * 1983-06-27 1988-01-26 Queen's University At Kingston Method for controlling bleeding
US5017556A (en) * 1986-11-04 1991-05-21 Genentech, Inc. Treatment of bleeding disorders using lipid-free tissue factor protein
EP0266993B1 (en) 1986-11-04 1995-04-05 Genentech, Inc. Method and therapeutic compositions for the treatment of bleeding disorders
US6239101B1 (en) * 1989-07-05 2001-05-29 Oklahoma Medical Research Foundation Thrombin binding polypeptides
US6238875B1 (en) * 1991-03-12 2001-05-29 The Scripps Research Institute Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
WO1994002172A1 (en) * 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
US5441759A (en) * 1992-09-03 1995-08-15 Sherwood Medical Company Method to stabilize TDMAC heparin coating
WO1996040921A1 (en) * 1995-06-07 1996-12-19 Ortho Farmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
CA2335274A1 (en) * 1998-07-15 2000-01-27 Genentech, Inc. Tissue factor protein variants with increased affinity for coagulation factor fvii/fviia
AU1458500A (en) * 1998-10-30 2000-05-22 Jonathan L. Miller Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein IB alpha
AU2002211686A1 (en) 2000-10-13 2002-04-22 On Site Gas Systems, Inc. Bandage using molecular sieves
US7015193B2 (en) * 2001-04-20 2006-03-21 University Of Vermont Compositions and methods to control bleeding
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
JP2008504033A (ja) * 2004-06-25 2008-02-14 アルター・バイオサイエンス・コーポレーション 植物に於ける組織因子の産生

Also Published As

Publication number Publication date
EP1915175A2 (en) 2008-04-30
WO2007014771A1 (en) 2007-02-08
EP1917026B1 (en) 2014-03-05
CN101291686B (zh) 2013-03-13
TW200744633A (en) 2007-12-16
EP1917026A1 (en) 2008-05-07
BRPI0616535B8 (pt) 2021-05-25
BRPI0616535B1 (pt) 2019-11-12
WO2007014772A3 (en) 2007-04-12
AU2006274979B2 (en) 2012-12-13
JP5268638B2 (ja) 2013-08-21
EP1749536A1 (en) 2007-02-07
ES2468225T3 (es) 2014-06-16
ES2468225T9 (es) 2014-10-24
WO2007014772A2 (en) 2007-02-08
HK1119569A1 (zh) 2009-03-13
KR101362993B1 (ko) 2014-02-21
PL1917026T3 (pl) 2014-08-29
BRPI0616535A2 (pt) 2011-06-21
DK1917026T3 (da) 2014-06-10
CA2617534A1 (en) 2007-02-08
KR20080043324A (ko) 2008-05-16
CN101291686A (zh) 2008-10-22
TWI441645B (zh) 2014-06-21
EP1917026B9 (en) 2014-06-18
JP2009503008A (ja) 2009-01-29
AU2006274979A1 (en) 2007-02-08
JP2009503009A (ja) 2009-01-29
CA2617534C (en) 2016-07-05

Similar Documents

Publication Publication Date Title
IL190733A0 (en) Methods and compositions for use in treatment of patients with autoantibody positive diseases
LT1799269T (lt) Oligoribonukleotidai ir jų naudojimo būdai alopecijos, ūminio inkstų nepakankamumo ir kitų ligų gydymui
AU2016216625A1 (en) Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
PL1682126T3 (pl) Podstawione benzazole i ich zastosowanie jako inhibitorów kinazy Raf
MY153198A (en) Inhibitors of protein aggregation
EP1948301A4 (en) TREATMENT OF BRONCHIC CONSTRICTION BY ELECTRICAL STIMULATION
IN2005DE03350A (zh)
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
ZA201201391B (en) Methods, compositions, and kits for the treatment of medical conditions
WO2004004658A3 (en) Methods and compositions relating to isoleucine boroproline compounds
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1835964A4 (en) WIRELESS CARDIAC SYSTEM FOR STIMULATION AND TREATMENT OF ARRHYTHMIA
PL1853158T3 (pl) Układ do zrównoważonego monitorowania fizjologicznego i leczenia
WO2003087831A3 (en) Proteins involved in breast cancer
TW200744628A (en) Stimulators of factor X activated (FXA) as new topical antihemorrhagic agents
NO20055390D0 (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
GB0416508D0 (en) Therapeutic agents
EP1708757A4 (en) USE OF PLURIPOTENTIAL CELLS TAKEN FROM HUMAN CORDIAL BLOOD BLOOD FOR THE TREATMENT OF DISEASE
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
WO2007130501A3 (en) Combination therapy for treatment of cancer
EP1773882A4 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
EP1773860A4 (en) METHOD FOR IDENTIFYING THE RISK OF TYPE II DIABETES AND TREATING THEREOF
IL186780A0 (en) Combination therapy in the treatment of cancer

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees